{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:58:06Z","timestamp":1793426286454,"version":"4.5.0"},"reference-count":88,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin intervent Radiol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral artery disease (PAD) is a common type of atherosclerotic disease of the lower extremities associated with reduced quality of life and ambulatory capacity. Major adverse cardiovascular events and limb amputations are the leading cause of morbidity and mortality in this population. Optimal medical therapy is therefore critical in these patients to prevent adverse events. Risk factor modifications, including blood pressure control and smoking cessation, in addition to antithrombotic agents, peripheral vasodilators, and supervised exercise therapy are key pillars of medical therapy. Revascularization procedures represent key touch points between patients and health care providers and serve as opportunities to optimize medical therapy and improve long-term patency rates and outcomes. This review summarizes the aspects of medical therapy that all providers should be familiar with when caring for patients with PAD in the peri-revascularization period.<\/jats:p>","DOI":"10.1055\/s-0043-57257","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T22:33:34Z","timestamp":1686954814000},"page":"119-128","source":"Crossref","is-referenced-by-count":4,"title":["Medical Management of Peripheral Artery Disease"],"prefix":"10.1055","volume":"40","author":[{"given":"Alexander E.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Beckman","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2016.11.008","article-title":"2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"69","author":"M D Gerhard-Herman","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref2","first-page":"6","article-title":"Lower extremity peripheral artery disease and quality of life among older individuals in the community","volume":"6","author":"A Wu","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"e185239","DOI":"10.1001\/jamanetworkopen.2018.5239","article-title":"Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease: a secondary analysis of the EUCLID trial","volume":"1","author":"J A Gutierrez","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"18","key":"ref4","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2017.02.064","article-title":"Underuse of prevention and lifestyle counseling in patients with peripheral artery disease","volume":"69","author":"J S Berger","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"e2136014","DOI":"10.1001\/jamanetworkopen.2021.36014","article-title":"Prescribing of statins after lower extremity revascularization procedures in the US","volume":"4","author":"N Singh","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jvs.2014.08.064","article-title":"Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease","volume":"60","author":"E J Armstrong","year":"2014","journal-title":"J Vasc Surg"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/heartjnl-2013-304082","article-title":"Meta-analysis of the association between cigarette smoking and peripheral arterial disease","volume":"100","author":"L Lu","year":"2014","journal-title":"Heart"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamacardio.2021.3987","article-title":"Smoking cessation improves outcomes in patients with peripheral artery disease","volume":"7","author":"M A Creager","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacc.2019.05.049","article-title":"Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases","volume":"74","author":"N Ding","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1016\/j.jvs.2014.12.009","article-title":"Society for Vascular Surgery Practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction","volume":"61","author":"M S Conte","year":"2015","journal-title":"J Vasc Surg"},{"issue":"25","key":"ref11","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.jacc.2010.07.031","article-title":"Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial","volume":"56","author":"D Hennrikus","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"R M Anthenelli","year":"2016","journal-title":"Lancet"},{"issue":"08","key":"ref13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.7326\/M15-0171","article-title":"Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. Preventive Services Task Force","volume":"163","author":"C D Patnode","year":"2015","journal-title":"Ann Intern Med"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11886-019-1129-5","article-title":"Dyslipidemia profiles in patients with peripheral artery disease","volume":"21","author":"A W Aday","year":"2019","journal-title":"Curr Cardiol Rep"},{"issue":"21","key":"ref15","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1161\/CIRCULATIONAHA.118.035432","article-title":"Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence","volume":"138","author":"A W Aday","year":"2018","journal-title":"Circulation"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1067\/mhj.2002.122871","article-title":"Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study","volume":"143","author":"J M Murabito","year":"2002","journal-title":"Am Heart J"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.96.1.44","article-title":"Intermittent claudication. A risk profile from the Framingham Heart Study","volume":"96","author":"J M Murabito","year":"1997","journal-title":"Circulation"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1078-5884(96)80170-5","article-title":"The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia","volume":"11","author":"I Smith","year":"1996","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"25","key":"ref19","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"S M Grundy","year":"2019","journal-title":"Circulation"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9149(97)00904-1","article-title":"Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)","volume":"81","author":"T R Pedersen","year":"1998","journal-title":"Am J Cardiol"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","author":"Heart Protection Study Collaborative Group","year":"2007","journal-title":"J Vasc Surg"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"issue":"14","key":"ref23","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.117.032361","article-title":"Association of statin dose with amputation and survival in patients with peripheral artery disease","volume":"137","author":"S Arya","year":"2018","journal-title":"Circulation"},{"key":"ref24","first-page":"415","article-title":"Ezetimibe therapy: mechanism of action and clinical update","volume":"8","author":"B A Phan","year":"2012","journal-title":"Vasc Health Risk Manag"},{"issue":"25","key":"ref25","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"C P Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2011.04.005","article-title":"The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline","volume":"218","author":"A M West","year":"2011","journal-title":"Atherosclerosis"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"M P Bonaca","year":"2018","journal-title":"Circulation"},{"issue":"20","key":"ref28","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial","volume":"141","author":"G G Schwartz","year":"2020","journal-title":"Circulation"},{"issue":"06","key":"ref29","first-page":"CD009744","article-title":"Niacin for primary and secondary prevention of cardiovascular events","volume":"6","author":"S Schandelmaier","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"ref30","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"H N Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"20","key":"ref31","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"M Miller","year":"2011","journal-title":"Circulation"},{"issue":"15","key":"ref32","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1161\/CIR.0000000000000482","article-title":"Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association","volume":"135","author":"D S Siscovick","year":"2017","journal-title":"Circulation"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"D L Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"ref34","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH Randomized Clinical Trial","volume":"324","author":"S J Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.121.054539","article-title":"Summoning STRENGTH to question the placebo in REDUCE-IT","volume":"144","author":"J A Bostrom","year":"2021","journal-title":"Circulation"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fimmu.2015.00098","article-title":"Platelets in inflammation and atherogenesis","volume":"6","author":"H M Nording","year":"2015","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"947645","DOI":"10.3389\/fcvm.2022.947645","article-title":"Understanding study drug discontinuation through EUCLID","volume":"9","author":"E H Weissler","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"18","key":"ref38","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials","volume":"301","author":"J S Berger","year":"2009","journal-title":"JAMA"},{"issue":"09","key":"ref39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"F G Fowkes","year":"2010","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"J Belch","year":"2008","journal-title":"BMJ"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2796.2006.01763.x","article-title":"Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial","volume":"261","author":"M Catalano","year":"2007","journal-title":"J Intern Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"21","key":"ref43","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"M P Bonaca","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"ref44","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS Trial","volume":"71","author":"S S Anand","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"ref45","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"J W Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"S S Anand","year":"2018","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"issue":"11","key":"ref48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/2047487314533215","article-title":"Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial","volume":"22","author":"M R Patel","year":"2015","journal-title":"Eur J Prev Cardiol"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"W R Hiatt","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"ref51","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"D L Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"P P Cacoub","year":"2009","journal-title":"Eur Heart J"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"J J Belch","year":"2010","journal-title":"J Vasc Surg"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.carrev.2016.07.006","article-title":"Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: meta-analysis of randomized controlled trials","volume":"18","author":"Z Fanari","year":"2017","journal-title":"Cardiovasc Revasc Med"},{"issue":"23","key":"ref55","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/CIRCULATIONAHA.120.050465","article-title":"Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety","volume":"142","author":"W R Hiatt","year":"2020","journal-title":"Circulation"},{"issue":"18","key":"ref56","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jacc.2018.08.002","article-title":"Pathology of peripheral artery disease in patients with critical limb ischemia","volume":"72","author":"N Narula","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1161\/01.CIR.98.11.1064","article-title":"Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results","volume":"98","author":"S S Anand","year":"1998","journal-title":"Circulation"},{"issue":"13","key":"ref58","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"M Hurlen","year":"2002","journal-title":"N Engl J Med"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"S Anand","year":"2007","journal-title":"N Engl J Med"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"J L Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"ref61","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0002-9149(02)02869-2","article-title":"Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication","volume":"90","author":"P D Thompson","year":"2002","journal-title":"Am J Cardiol"},{"issue":"06","key":"ref62","first-page":"CD003748","article-title":"Cilostazol for intermittent claudication","volume":"6","author":"T Brown","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1358863X10361545","article-title":"A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication","volume":"15","author":"R L Pande","year":"2010","journal-title":"Vasc Med"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvs.2007.10.009","article-title":"Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a study in long-term effects)","volume":"47","author":"W R Hiatt","year":"2008","journal-title":"J Vasc Surg"},{"issue":"21","key":"ref65","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"M Packer","year":"1991","journal-title":"N Engl J Med"},{"issue":"17","key":"ref66","first-page":"e426","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"138","author":"P K Whelton","year":"2018","journal-title":"Circulation"},{"issue":"09","key":"ref67","doi-asserted-by":"crossref","first-page":"e006512","DOI":"10.1161\/CIRCOUTCOMES.120.006512","article-title":"Association of hypertension and arterial blood pressure on limb and cardiovascular outcomes in symptomatic peripheral artery disease: the EUCLID Trial","volume":"13","author":"M Fudim","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"17","key":"ref68","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1161\/CIRCULATIONAHA.118.033348","article-title":"Association of blood pressure measurements with peripheral artery disease events","volume":"138","author":"N K Itoga","year":"2018","journal-title":"Circulation"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.109.142240","article-title":"Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR\/Trandolapril STudy","volume":"55","author":"A A Bavry","year":"2010","journal-title":"Hypertension"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ehj.2003.10.033","article-title":"Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease","volume":"25","author":"J Ostergren","year":"2004","journal-title":"Eur Heart J"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"S Yusuf","year":"2000","journal-title":"N Engl J Med"},{"issue":"15","key":"ref72","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"S Yusuf","year":"2008","journal-title":"N Engl J Med"},{"issue":"13","key":"ref73","doi-asserted-by":"crossref","first-page":"e700","DOI":"10.1161\/CIR.0000000000000727","article-title":"Implementation of supervised exercise therapy for patients with symptomatic peripheral artery disease: a science advisory from the American Heart Association","volume":"140","author":"D Treat-Jacobson","year":"2019","journal-title":"Circulation"},{"issue":"01","key":"ref74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1358863X07084911","article-title":"The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program","volume":"13","author":"J G Regensteiner","year":"2008","journal-title":"Vasc Med"},{"issue":"04","key":"ref75","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jama.292.4.453","article-title":"Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms","volume":"292","author":"M M McDermott","year":"2004","journal-title":"JAMA"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2008.962","article-title":"Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial","volume":"301","author":"M M McDermott","year":"2009","journal-title":"JAMA"},{"issue":"21","key":"ref77","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1001\/jama.2017.17437","article-title":"Effect of granulocyte-macrophage colony-stimulating factor with or without supervised exercise on walking performance in patients with peripheral artery disease: the PROPEL Randomized Clinical Trial","volume":"318","author":"M M McDermott","year":"2017","journal-title":"JAMA"},{"issue":"04","key":"ref78","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jvs.2012.04.046","article-title":"Supervised walking therapy in patients with intermittent claudication","volume":"56","author":"F Fakhry","year":"2012","journal-title":"J Vasc Surg"},{"issue":"04","key":"ref79","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1078-5884(96)80171-7","article-title":"Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial","volume":"11","author":"J M Perkins","year":"1996","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"01","key":"ref80","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/CIRCULATIONAHA.111.075770","article-title":"Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study","volume":"125","author":"T P Murphy","year":"2012","journal-title":"Circulation"},{"issue":"01","key":"ref81","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/bjs.10324","article-title":"Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease","volume":"104","author":"F A Mazari","year":"2017","journal-title":"Br J Surg"},{"issue":"02","key":"ref82","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1148\/radiol.2501080607","article-title":"Intermittent claudication: clinical effectiveness of endovascular revascularization versus supervised hospital-based exercise training -- randomized controlled trial","volume":"250","author":"S Spronk","year":"2009","journal-title":"Radiology"},{"issue":"12","key":"ref83","first-page":"1125","article-title":"Supervised exercise therapy and revascularization for intermittent claudication: network meta-analysis of randomized controlled trials","volume":"12","author":"A Saratzis","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"06","key":"ref84","doi-asserted-by":"crossref","first-page":"e1035","DOI":"10.1097\/SLA.0000000000004712","article-title":"Long-term follow-up of a randomized clinical trial comparing endovascular revascularization plus supervised exercise with supervised exercise only for intermittent claudication","volume":"276","author":"S Klaphake","year":"2020","journal-title":"Ann Surg"},{"issue":"04","key":"ref85","first-page":"CD005263","article-title":"Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication","volume":"4","author":"D Hageman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"05","key":"ref86","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/CIRCULATIONAHA.110.963066","article-title":"Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial","volume":"123","author":"A W Gardner","year":"2011","journal-title":"Circulation"},{"issue":"06","key":"ref87","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.jvs.2013.08.034","article-title":"Community walking programs for treatment of peripheral artery disease","volume":"58","author":"R J Mays","year":"2013","journal-title":"J Vasc Surg"},{"issue":"18","key":"ref88","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"M S Sabatine","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Seminars in Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-57257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T22:34:30Z","timestamp":1686954870000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-57257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":88,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,6,16]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-57257","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0739-9529","1098-8963"],"issn-type":[{"value":"0739-9529","type":"print"},{"value":"1098-8963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}